Clinical Trial

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2024 (before its estimated December 20, 2025 completion). Its status may not reflect the trial's current state.
Summary
This prospective clinical study aims to evaluate and observe the efficacy and safety of Atezolizumab combined with Apatinib in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design. The study is planned to be conducted in Shaanxi Province, China, with an initial target enrollment of 60 patients. The study commenced in February 2024, and recruitment is expected to conclude around December 2025, with the trial anticipated to end by December 2026. Assuming no occurrences such as withdrawal of informed consent by subjects, intolerable adverse drug reactions, or investigator-assessed unsuitability for further participation, each participant's estimated duration of study treatment will continue until radiographically confirmed tumor progression.
Trial Details
NCT Number NCT06475209
Lead Sponsor Tang-Du Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions SCLC
Enrollment 60 participants
Start Date 2024-06-20
Primary Completion 2025-12-20 (estimated)
Study Completion 2026-12-20 (estimated)
Updated on ClinicalTrials.gov 2024-06-26